Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00113282 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study Identification, Study Status, Referencesv13
  2. 2 versions Re-verified since Jun 10, 2009, no change to tracked fieldsv11-v12
  3. Study title expanded, about 1 wordv10 See this version in full on ClinicalTrials.gov ↗
  4. Completion date: Dec 2007 to Feb 2008v9
  5. Enrollment target: 98 to 57 Secondary endpoints: 13 to 14 · Study description expanded, about 22 wordsv8 Show 2 more changesShow less
    • Secondary endpoints: 13 to 14
    • Study description expanded, about 22 words

    See this version in full on ClinicalTrials.gov ↗

Show 6 earlier versionsHide 6 earlier versions
  1. Trial status: Active, Not Recruiting to Completed Primary completion date: Dec 2007v7 Show 1 more changeShow less
    • Primary completion date: Dec 2007
  2. Completion date: Dec 2007v6
  3. Collaborators expanded, about 2 wordsv5 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Recruiting to Active, Not Recruiting Site details revisedv4 Show 1 more changeShow less
    • Site details revised
  5. 2 versions Re-verified since Jun 30, 2005, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients with a CD4 cell count over 200/mm3, but its activity in patients with treatment failure and low CD4 cell counts is unknown. This study will test the efficacy and safety of IL-2 with an optimized antiretroviral regimen in patients with a CD4 count below 200/mm3 and a plasma viral load above 10,000 HIV RNA copies/ml.
Trial Details
NCT Number NCT00113282
Lead Sponsor French National Agency for Research on AIDS and Viral Hepatitis
Collaborators: Chiron Corporation
Conditions HIV Infections
Enrollment 57 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov